Provided by Tiger Trade Technology Pte. Ltd.

Sana Biotechnology, Inc.

3.91
+0.17004.55%
Post-market: 3.86-0.0500-1.28%19:54 EDT
Volume:2.93M
Turnover:11.55M
Market Cap:1.17B
PE:-5.12
High:4.10
Open:3.78
Low:3.74
Close:3.74
52wk High:6.55
52wk Low:2.61
Shares:299.00M
Float Shares:191.00M
Volume Ratio:0.91
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7636
EPS(LYR):-0.9642
ROE:-152.87%
ROA:-29.16%
PB:7.56
PE(LYR):-4.06

Loading ...

Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA)

TIPRANKS
·
Aug 17

BofA Securities Adjusts Sana Biotechnology Price Target to $6 From $7

MT Newswires Live
·
Aug 14

Bank of America Securities Keeps Their Buy Rating on Sana Biotechnology (SANA)

TIPRANKS
·
Aug 14

MiNK Therapeutics Q2 Loss Narrows on Expense Discipline

Reuters
·
Aug 13

Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss

Reuters
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), Pfizer (PFE) and Sana Biotechnology (SANA)

TIPRANKS
·
Aug 12

Simris Alg Q2 Ebitda Loss Narrows

Reuters
·
Aug 12

Sana Biotechnology (SANA) Receives a Buy from Wedbush

TIPRANKS
·
Aug 11

Sana Biotechnology Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

Vera Therapeutics Q2 Loss Widens Less than Expected

Reuters
·
Aug 11

Sana Biotechnology Q2 Adj. EPS $(0.13) Beats $(0.15) Estimate

Benzinga Earnings
·
Aug 11

Sana Biotechnology Q2 Adjusted Loss Narrows, Beats Estimates

Reuters
·
Aug 11

Sana Biotechnology Q2 FY26 Net Loss Narrows to $63.64 Million; Loss Per Share Improves to $0.22 GAAP

Reuters
·
Aug 11

Sana Biotechnology Q2 Adjusted EPS USD -0.13 Vs. IBES Estimate USD -0.15

Reuters
·
Aug 11

Sana Biotechnology Q2 EPS USD -0.22

THOMSON REUTERS
·
Aug 11

Sana Biotechnology Inc: Q2 2026 Cash Position of $160.5 Million; Expected Cash Runway into Mid-2027

THOMSON REUTERS
·
Aug 11

U.S. Earnings Preview: After Market Close Aug. 7

Dow Jones
·
Aug 08

Sana Biotechnology Plans IND Filing, Targets Phase 1/2 Start This Year for SC451 Type 1 Diabetes Therapy

Reuters
·
Jul 13

Sana Biotechnology (SANA) Is Up 18.1% After Removal From Key Russell Value Indexes - What's Changed

Simply Wall St.
·
Jul 09

Sana Biotechnology to Present First-in-human Hypoimmune Islet Transplant Data at EASD 2026

Reuters
·
Jul 01